High Intensity Contact Ultrasound Interstitial Medical Device

The Sonoprobe Medical Device

SonoProbe is a diagnostic and therapeutic treatment probe percutaneously introduced in a tumor under local anaesthesia. Slightly larger than a biospy needle, the SonoProbe is composed of dozens of miniaturized ultrasound transducers that are able to emit high intensity ultrasound waves for therapy.

Treatments with the SonoProbe are continuously monitored and controlled by software that interfaces with an MR imaging system, performs treatment simulations, and executes treatments with real-time temperature feedback control.

In the figure below, the color code corresponds to heating of brain tissue around the probe. On this figure, the probe is artificially represented for clarity, as the probe is nearly invisible on the MR images.

This innovation and development are currently in pre-clinical testing, which will soon allow for an application in humans for the treatment of brain tumors.  




  • unnamed-2

  • News CarThera

    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

    ASCO 2018: CarThera presents promising preliminary efficacy data for treating recurrent glioblastoma

    Preliminary data from the first clinical trial of the company’s intracranial ultrasound implant, SonoCloud®, show a good safety profile and promising trends in overall survival.

    Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase 1/2a clinical trial (NCT02253212) presented a preliminary analysis of the data from 21 glioblastoma patients who received 65 SonoCloud® treatments. Overall Survival was increased from 8.5 to 12.9 months in patients who had SonoCloud®-induced BBB opening.

    May 2018 – CarThera will participate to BIO 2018 in Boston

    CarThera will participate to the BIO International Convention in Boston on June 4-7 to meet with global biotech and pharma leaders and showcase its SonoCloud device.

    Should you want to meet us at BIO and hear more about SonoCloud – our ultrasound device, aimed at improving treatment efficiency by temporarily opening the Blood Brain Barrier – contact us at and come to Booth 527 at the France Pavilion.